Member Info for daveycaferacer

typical small Company AGM then

it's not happening, but of it did, you'd get NASDAQ shares if your Broker is capable of holding them, and if they aren't you'd have to change Broker - it's an easy seamless process, just a bit of admin, but it's not happening

it is not "coming soon"

At the General Meeting of the Company held at 11.00 a.m. on 6 May 2020, the resolutions to seek additional authorities to issue shares, to disapply pre-emption rights, replacement of option grants and adoption of new articles of association, were duly passed.

The results of the proxy voting will be available shortly on the Company's website, www.tizianalifesciences.com.

Abstracts released on the 13th, Meeting 29th - 31st ;o-)

you won't be able to join unless you have the proxy form with the ID number, as it is not a public meeting, it is a meeting for Shareholders who appear on the Register

You needed to have received the Proxy forms, but only if you are on the Shareholder register, unfortunately most people hold shares via the Broker in nominee form only

It is unlikely the AGM will include any material news, it's a formality really

The meeting takes place at 11.00 a.m. on 6 May 2020.
To join the meeting type (or paste) the following web address into your web browser:
https://mmitc.webex.com/mmitc/onstage/g.php?MTID=ede6efe3ac1fad2161845b315f3a8fff1
You will be asked to enter a password to gain access to the meeting. This code can be found on the bottom
section of your proxy form. Please detach and keep this portion of the proxy form before returning the
proxy form.

It's interesting that our new large Shareholder Morris Silverman is Chairman of Diasys Diagnostics, so knows the diagnostics landscape. Could there be a tie-up between the two Companies? ASCO is not only a scientific meeting, it's often where commercial tie-ups and deals are done.

https://www.diasys-diagnostics.com/

In the United States most small Biotechs get bought out by big pharma as they try to address their patent cliffs. This typically happens around the time when a lead asset transitions from P2 to P3 and the capex requirements go up signiicantly, but equally the lead candidates chance of success also increases dramatically. Here we have the added dynamic that a cancer test is also in the portfolio, which could be of added interest to big pharma. ASCO will put TILS on the radar of big pharma.

indeed = 55p

also worth noting with ADR's for those unfamiliar with the concept:-

When you instruct your broker to buy ordinary shares on your behalf, your broker will have the option of buying DIs on AIM, or buying Nasdaq listed ADRs. Conversely, when you wish to sell your position, your broker will either sell them on AIM, or otherwise, may sell them on the Nasdaq market. Any necessary conversion of securities would first be effected in the manner described above. In any event, this would be a seamless process for shareholders. Unless they particularly wish to give specific instructions in that regard (in which case they are free to do so) shareholders will not need to be concerned with which market their shares are purchased from or sold into. Brokers will simply buy or sell in the market where there is the most liquidity at that time.

same on NASDAQ folks, big big buys

big gap up on NASDAQ today

btw for anyone interested, MM's can shift between ADR's and OS's so some OS trades may result in a shift to ADR's and vice versa.

When you instruct your broker to buy ordinary shares on your behalf, your broker will have the option of buying DIs on AIM, or buying Nasdaq listed ADRs. Conversely, when you wish to sell your position, your broker will either sell them on AIM, or otherwise, may sell them on the Nasdaq market. Any necessary conversion of securities would first be effected in the manner described above. In any event, this would be a seamless process for shareholders. Unless they particularly wish to give specific instructions in that regard (in which case they are free to do so) shareholders will not need to be concerned with which market their shares are purchased from or sold into. Brokers will simply buy or sell in the market where there is the most liquidity at that time.

lots of people buying ADR's, that's all

exactly, they are not de-listing ;o-)

If they de-list from AIM they will concurrently cancel the ADR's and have their Bermuda shares listed on NASDAQ instead (similar to existing ADR's). In my experience you will be allocated equivalent NASDAQ listed equivalent ADR's. Not sure what happens if your Broker can't support NASDAQ stosk (my Broker can, so it's not been an issue for me)

"Gilead – a leader in the Covid battle with its anti-viral drug Remdesivir, confirmed it is evaluating different formulations – including delivery via inhaler. "

Pity so many people do not know the difference between a Nebulizer and an Inhaler. Tiziana will administer the treatment using a Nebulizer.

Average volume in UK = 820k
Todays volume = 2.3m

ASCO coming up and that will be fantastic for Tiziana, especially given the fact that specialist Analysts look out for first or best in class assets from small Biotechs. The breast cancer test will generate a lot of interest within the specialist Biotech Investment community in the United States.